673
Participants
Start Date
February 29, 2004
Primary Completion Date
August 31, 2005
Study Completion Date
August 31, 2005
Epoetin alfa or beta
intravenously 3 times weekly for 52 weeks, as prescribed
RO0503821 (1x/2 Weeks)
60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.
RO0503821 (1x/4 Weeks)
120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.
Lausanne
Lausanne
Lillehammer
Bergen
Trondheim
Levanger
New York
New York
The Bronx
Great Neck
Brooklyn
Mineola
A Coruña
Pittsburgh
Pittsburgh
Erie
Philadelphia
Milan
Fairfax
Como
Richmond
Lecco
Lodi
Pavia
Raleigh
Madrid
Málaga
Orangeburg
Atlanta
Augusta
Toulouse
Pembroke Pines
Bordeaux
Ocala
Birmingham
Montgomery
Mobile
Nashville
Nashville
Chattanooga
La Tronche
Seville
Toledo
Dortmund
Marshfield
Brooklyn Center
Maywood
Chicago
Wiesbaden
Wiesloch
Stuttgart
Covington
Ellwangen
Paris
Paris
Houston
Houston
San Antonio
Austin
Lakewood
Denver
München
Colorado Springs
Albuquerque
Los Angeles
Nuremberg
Encino
Monterey Park
San Diego
Riverside
Irvine
Aubervilliers
San Francisco
Portland
Sacramento
San Diego
San Jose
Louisville
Boston
Boston
Springfield
Detroit
Paterson
Stony Brook
Chapel Hill
Winston-Salem
Cincinnati
Burlington
St. John's
Kingston
London
Mississauga
Scarborough Village
Toronto
Toronto
Montreal
Saskatoon
Paris
Barcelona
Hoffmann-La Roche
INDUSTRY